Unfortunately, its clinical utility has been limited due to multiple mechanisms of TRAIL resistance.18,19 Colon cancer is a leading cause of cancer-related mortality for which targeted therapy is critically needed; however, clinical trials using TRAIL monotherapy have shown no response in these patients, and we similarly have demonstrated TRAIL resistance in the majority of human colon cancer cell lines tested. Here, TNFSF10 is linked to colonic neoplasm.